Citius Pharmaceuticals, Inc. (CTXR)

NASDAQ: CTXR · IEX Real-Time Price · USD
0.897
+0.073 (8.88%)
At close: Mar 28, 2024, 4:00 PM
0.910
+0.013 (1.40%)
After-hours: Mar 28, 2024, 7:57 PM EDT

Company Description

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy.

It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.

The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals logo
Country United States
Founded 2007
Industry Biotechnology
Sector Healthcare
Employees 22
CEO Leonard L. Mazur

Contact Details

Address:
11 Commerce Drive, 1st Floor
Cranford, New Jersey 07016
United States
Phone (908) 967-6676
Website citiuspharma.com

Stock Details

Ticker Symbol CTXR
Exchange NASDAQ
Fiscal Year October - September
Reporting Currency USD
CIK Code 0001506251
CUSIP Number 17322U207
ISIN Number US17322U2078
Employer ID 27-3425913
SIC Code 2834

Key Executives

Name Position
Leonard L. Mazur Co-Founder, Chief Executive Officer, Chairman and Secretary
Myron Z. Holubiak Co-Founder and Executive Vice Chairman
Dr. Myron S. Czuczman M.D. Executive Vice President and Chief Medical Officer
Jaime Bartushak Chief Business Officer, Chief Financial Officer and Chief Accounting Officer
Gary F. Talarico Executive Vice President of Operations
Ilanit Allen Vice President of Investor Relations and Corporate Communications
Dr. Alan Lader Ph.D. Senior Vice President and Head of Clinical Operations and Quality Assurance
Dhananjay G. Wadekar Senior Vice President of Business Strategy
Kelly Creighton Ph.D. Executive Vice President of Chemistry, Manufacturing and Controls
Nikolas Burlew Executive Vice President of Quality Assurance

Latest SEC Filings

Date Type Title
Mar 18, 2024 8-K Current Report
Mar 13, 2024 8-K Current Report
Mar 1, 2024 EFFECT Notice of Effectiveness
Feb 23, 2024 S-3 Registration statement under Securities Act of 1933
Feb 23, 2024 S-8 Securities to be offered to employees in employee benefit plans
Feb 15, 2024 8-K Current Report
Feb 14, 2024 10-Q Quarterly Report
Feb 14, 2024 8-K Current Report
Jan 31, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Jan 26, 2024 ARS Filing